부산대학교 도서관

Background & Aims: Worldwide, colorectal cancer (CRC) is the third most common cancer in men and second in women. The aim of the current study was to identify whether the mi-375 is indeed down-regulated in metastatic CRC and if it could be considered as a potential minimally invasive prognostic biomarker for CRC. Methods. Exosomes were isolated and characterized from patients with liver metastasis from CCR. The characterization of exosome was performed using TEM/SEM. HCT116 cells were treated with mi-375 mimic, NSM and mi-375 inhibitor. Functional assays included cell counting assay for 14 days, Matrigel invasion assay, apoptosis assay by flow cytometry using Annexin V-FITC, RT-PCR and Western blotting. Results. Increased proliferation potential was proven for the cells transfected with mi-375 inhibitor, while the mi-375 mimic decreased the cell number. The cells transfected with the mi-375 inhibitor are aggressive and cross the membrane; 3.84% of the cells transfected with the mi-375 inhibitor entered apoptosis, while 6.45% of those transfected with the non-specific mimic were in programmed cell death, less than those transfected with the microRNA. RT-PCR for Bcl-2 expression showed that Bcl-2 is down-regulated for mi-375 inhibitor and up-regulated for the mi-375 mimic, a result confirmed by Western blotting. Conclusion. The present study brings to the forefront new data that suggest mi-375 as a new player in controlling the pathways responsible for inhibiting the natural history of CRC tumor cells, via the Bcl-2 pathway. [ABSTRACT FROM AUTHOR]